[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595865":3},{"organization":4,"armGroups":7,"interventions":53,"overallOfficials":11,"centralContacts":59,"locations":65,"responsibleParty":83,"collaborators":85,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":11,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":11,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14,17,20,23,26,29,32,35,38,41,44,47,50],{"label":9,"type":10,"description":11,"interventionNames":12},"dose level 1 of SPGL008 （Intravenous administration）","EXPERIMENTAL",null,[13],"Drug: SPGL008",{"label":15,"type":10,"description":11,"interventionNames":16},"dose level 2 of SPGL008 （Intravenous administration）",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"dose level 3 of SPGL008 （Intravenous administration）",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"dose level 4 of SPGL008 （Intravenous administration）",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"dose level 5 of SPGL008 （Intravenous administration）",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"dose level 6 of SPGL008 （Intravenous administration）",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"dose level 7 of SPGL008 （Intravenous administration）",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"dose level 8 of SPGL008 （Intravenous administration）",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"dose level 1 of SPGL008 （Subcutaneous administration）",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"dose level 2 of SPGL008 （Subcutaneous administration）",[13],{"label":42,"type":10,"description":11,"interventionNames":43},"dose level 3 of SPGL008 （Subcutaneous administration）",[13],{"label":45,"type":10,"description":11,"interventionNames":46},"dose level 4 of SPGL008 （Subcutaneous administration）",[13],{"label":48,"type":10,"description":11,"interventionNames":49},"dose level 5 of SPGL008 （Subcutaneous administration）",[13],{"label":51,"type":10,"description":11,"interventionNames":52},"dose level 6 of SPGL008 （Subcutaneous administration）",[13],[54],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":11},"DRUG","SPGL008","Biological product",[9,36,15,39,18,42,21,45,24,48,27,51,30,33],[60],{"name":61,"role":62,"phone":63,"phoneExt":11,"email":64},"yongsheng Li","CONTACT","17784310187","lys@cqu.edu.cn",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Chongqing University Cancer Hospital","RECRUITING","Chongqing","Chongqing Municipality","400030","China","CN",{"type":75,"coordinates":76},"Point",[77,78],106.55771,29.56026,{"lat":78,"lon":77},[81],{"name":82,"role":62,"phone":63,"phoneExt":11,"email":64},"yongshen LI",{"type":84,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[86],{"name":87,"class":88},"Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.","UNKNOWN","100595865","phase-1-a-phase-i-study-of-spgl008-in-subjects-with-advanced-malignant-tumors-100595865",false,"NCT07038005","A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n1. Males and\u002For females, 18-75 years old;\n2. Histologically and\u002For cytologically documented advanced or metastatic malignant Tumors;\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n4. Expected survival \\>=3 months;\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease;\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI-CTCAE\\] v.5.0);\n3. Inadequate organ or bone marrow function;\n4. Pregnant or breast-feeding woman;\n5. Known allergies, hypersensitivity, or intolerance to SPGL008.","ALL","18 Years","75 Years",{"count":100,"type":101},96,"ESTIMATED","INTERVENTIONAL",[104],"PHASE1","This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.",[107],"Advanced Malignant Tumors","2026-02-05",{"date":110,"type":111},"2026-02-09","ACTUAL",{"date":113,"type":111},"2025-07-30",{"date":115,"type":101},"2027-06-08",{"name":5,"class":6},1]